Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interferon therapy reduces the risk for hepatocellular carcinoma.

Literature DB >> 11034573

Interferon therapy reduces the risk for hepatocellular carcinoma.

J L Brown¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2000 PMID： 11034573 PMCID： PMC1728124 DOI： 10.1136/gut.47.5.610

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

× No keyword cloud information.

9 in total

1. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

Authors: G Mazzella; E Accogli; S Sottili; D Festi; M Orsini; A Salzetta; V Novelli; A Cipolla; C Fabbri; A Pezzoli; E Roda
Journal: J Hepatol Date: 1996-02 Impact factor: 25.083

2. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors: A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal: Hepatology Date: 1998-05 Impact factor: 17.425

3. Determinants of outcome of compensated hepatitis C virus-related cirrhosis.

Authors: L Serfaty; H Aumaître; O Chazouillères; A M Bonnand; O Rosmorduc; R E Poupon; R Poupon
Journal: Hepatology Date: 1998-05 Impact factor: 17.425

4. 45-year follow-up of hepatitis C virus infection in healthy young adults.

Authors: L B Seeff; R N Miller; C S Rabkin; Z Buskell-Bales; K D Straley-Eason; B L Smoak; L D Johnson; S R Lee; E L Kaplan
Journal: Ann Intern Med Date: 2000-01-18 Impact factor: 25.391

5. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.

Authors: D C Valla; M Chevallier; P Marcellin; J L Payen; C Trepo; M Fonck; M Bourliere; E Boucher; J P Miguet; D Parlier; C Lemonnier; P Opolon
Journal: Hepatology Date: 1999-06 Impact factor: 17.425

6. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

Authors: G Fattovich; G Giustina; F Degos; F Tremolada; G Diodati; P Almasio; F Nevens; A Solinas; D Mura; J T Brouwer; H Thomas; C Njapoum; C Casarin; P Bonetti; P Fuschi; J Basho; A Tocco; A Bhalla; R Galassini; F Noventa; S W Schalm; G Realdi
Journal: Gastroenterology Date: 1997-02 Impact factor: 22.682

7. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

Authors: F Degos; C Christidis; N Ganne-Carrie; J P Farmachidi; C Degott; C Guettier; J C Trinchet; M Beaugrand; S Chevret
Journal: Gut Date: 2000-07 Impact factor: 23.059

8. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Authors: Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa
Journal: Ann Intern Med Date: 1998-07-15 Impact factor: 25.391

9. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors: S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal: Lancet Date: 1995-10-21 Impact factor: 79.321